Download the Agenda

Speaker Information

 Roy Baynes
Roy Baynes Senior VP, Global Clinical Development Merck, Sharp & Dohme

Main Conference Day 1

12:20 PM KEYNOTE ADDRESS: Gain an Overview of the Past, Present, and Future of Immune Checkpoint Modulation: What Has Already Been Accomplished, And What Is To Come?

• Reviewing the development of this revolutionary new
• Assessing the monoclonal and combination potential of
immune checkpoint inhibitors
• Overview of the developmental stages of immune checkpoint
inhibitors, from preclinical, to development, to approval
• Identifying the critical issues facing the development of cancer
immunotherapies and how we can overcome these issues
• Highlighting the importance of collaboration between
industry, academia, regulators, and advocacy groups to
advance cancer immunotherapies

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!


Become a Pharma IQ Member and receive our weekly newsletter!